5 Tiny Stocks That Are On Fire Right Now

4. Sutro Biopharma Inc. (NASDAQ:STRO)

Year-to-Date Performance: 183.15%

Sutro Biopharma Inc. (NASDAQ:STRO) is one of the tiny stocks that are on fire right now. On March 23, Sutro Biopharma reported its full-year 2025 financial results, highlighting a strengthened balance sheet and significant clinical milestones for its antibody-drug conjugate/ADC platform. The company ended 2025 with $141.4 million in cash and marketable securities, which, when combined with a recent $110 million capital raise, extends its cash runway into at least Q2 2028. This financial stability supports a sharpened focus on advancing both wholly owned and partnered oncology programs.

A major focus for 2026 is the progress of Sutro’s internal pipeline. The company completed dosing for the third cohort in its Phase 1 trial of STRO-004, a potential best-in-class Tissue Factor/TF ADC, with initial clinical data expected in mid-2026. Additionally, Sutro Biopharma Inc. (NASDAQ:STRO) is accelerating the development of STRO-227, its first wholly owned dual-payload program targeting PTK7, with an IND submission now targeted for 2026. The company also expects its ITGB6-targeting ADC, STRO-006, to enter clinical development this year.

Sutro’s collaboration with Astellas Pharma has also reached a key inflection point, with their first partnered dual-payload immunostimulatory ADC entering the clinic. Patient dosing is currently in Q2 2026. A second partnered program also advanced into IND-enabling toxicology studies late last year, further validating Sutro’s site-specific ADC platform through strategic partnerships.

Sutro Biopharma Inc. (NASDAQ:STRO) is a clinical-stage biotechnology company using a proprietary cell-free platform to develop next-gen antibody-drug conjugates/ADCs for cancer. By optimizing antibodies, linkers, and single or dual-payloads, the company aims to improve drug exposure and overcome treatment resistance in oncology markets with significant unmet needs.